Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Search
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The searchable portal provides a centralised location of cancer medicines that have been scored and published by ESMO.

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Agent
Tumour
Score
reset selection
Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Scorecard
Trastuzumab - Chemotherapy Adjuvant or neo-adjuvant HER2 positive tumours Breast Cancer Breast Cancer HER2+ Early
A
Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel (Randomised phase II study) Neo-adjuvant HER2 overexpressed invasive ductal breast Breast Cancer Breast Cancer HER2+ Early
C
T-DM1 - Lapatinib + capecitabine 2nd line metastatic after trastuzumab failure (extensive crossover) Breast Cancer Breast Cancer HER2+ Metastatic
4
Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel + placebo 1st line metastatic Breast Cancer Breast Cancer HER2+ Metastatic
4
Trastuzumab Lapatinib Lapatinib 3rd line metastatic Breast Cancer Breast Cancer HER2+ Metastatic
4
Palbociclib Fulvestrant Fulvestrant + placebo 2nd line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
4
Palbociclib Letrozole Letrozole + placebo 1st line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Palbociclib Letrozole Letrozole (Randomised phase II study) 1st line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Ribociclib Letrozole Letrozole + placebo 1st line metastatic post-menopause HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Lapatinib Capecitabine Capecitabine 2nd line metastatic after trastuzumab failure Breast Cancer Breast Cancer HER2+ Metastatic
3
Legal
Useful links
Subscribe to ESMO newsletters

Receive information and updates on ESMO’s scientific and educational resources, events, members activities.

To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH
© Copyright 2020 European Society for Medical Oncology All rights reserved worldwide.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings